These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 34119512)

  • 1. Relapse of minimal change disease following the AstraZeneca COVID-19 vaccine.
    Morlidge C; El-Kateb S; Jeevaratnam P; Thompson B
    Kidney Int; 2021 Aug; 100(2):459. PubMed ID: 34119512
    [No Abstract]   [Full Text] [Related]  

  • 2. Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine.
    Holzworth A; Couchot P; Cruz-Knight W; Brucculeri M
    Kidney Int; 2021 Aug; 100(2):463-464. PubMed ID: 34048824
    [No Abstract]   [Full Text] [Related]  

  • 3. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report.
    Leclerc S; Royal V; Lamarche C; Laurin LP
    Am J Kidney Dis; 2021 Oct; 78(4):607-610. PubMed ID: 34242687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal change disease and acute kidney injury following the Pfizer-BioNTech COVID-19 vaccine.
    D'Agati VD; Kudose S; Bomback AS; Adamidis A; Tartini A
    Kidney Int; 2021 Aug; 100(2):461-463. PubMed ID: 34000278
    [No Abstract]   [Full Text] [Related]  

  • 5. Primary adrenal insufficiency associated with Oxford-AstraZeneca ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia (VITT).
    Varona JF; García-Isidro M; Moeinvaziri M; Ramos-López M; Fernández-Domínguez M
    Eur J Intern Med; 2021 Sep; 91():90-92. PubMed ID: 34256983
    [No Abstract]   [Full Text] [Related]  

  • 6. Report of two cases of minimal change disease following vaccination for COVID -19.
    Baskaran K; Cohen AWS; Weerasinghe N; Vilayur E
    Nephrology (Carlton); 2022 Jan; 27(1):111-112. PubMed ID: 34779088
    [No Abstract]   [Full Text] [Related]  

  • 7. Minimal change disease relapse following SARS-CoV-2 mRNA vaccine.
    Kervella D; Jacquemont L; Chapelet-Debout A; Deltombe C; Ville S
    Kidney Int; 2021 Aug; 100(2):457-458. PubMed ID: 33964312
    [No Abstract]   [Full Text] [Related]  

  • 8. Exuberant lichenoid eruption after Oxford-AstraZeneca COVID-19 vaccine: a singular case.
    Correia C; Fernandes S; Soares-de-Almeida L; Filipe P
    J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):e268-e270. PubMed ID: 34913207
    [No Abstract]   [Full Text] [Related]  

  • 9. Nephrotic syndrome with minimal change disease after the Pfizer-BioNTech COVID-19 vaccine: two cases.
    Hartley JL; Bailey N; Sharma A; Shawki H
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35246429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination.
    Kim SH; Lee SY; Kim GY; Oh JS; Kim J; Chun KJ; Ju MH; Lee CH; Song YJ; Na JY
    J Korean Med Sci; 2022 Apr; 37(13):e104. PubMed ID: 35380028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inverse lichen planus post Oxford-AstraZeneca COVID-19 vaccine.
    Awada B; Abdullah L; Kurban M; Abbas O
    J Cosmet Dermatol; 2022 Mar; 21(3):883-885. PubMed ID: 34997985
    [No Abstract]   [Full Text] [Related]  

  • 12. Bullous Sweet syndrome following SARS-CoV-2 Oxford AstraZeneca vaccine.
    Žagar T; Hlača N; Brajac I; Prpić-Massari L; Peternel S; Kaštelan M
    Br J Dermatol; 2022 Mar; 186(3):e110. PubMed ID: 34817862
    [No Abstract]   [Full Text] [Related]  

  • 13. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
    Komaba H; Wada T; Fukagawa M
    Am J Kidney Dis; 2021 Sep; 78(3):469-470. PubMed ID: 34023417
    [No Abstract]   [Full Text] [Related]  

  • 14. Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine.
    Clayton-Chubb D; Schneider D; Freeman E; Kemp W; Roberts SK
    J Hepatol; 2021 Nov; 75(5):1249-1250. PubMed ID: 34171435
    [No Abstract]   [Full Text] [Related]  

  • 15. Onset/flare of psoriasis following the ChAdOx1 nCoV-19 Corona virus vaccine (Oxford-AstraZeneca/Covishield): Report of two cases.
    Nagrani P; Jindal R; Goyal D
    Dermatol Ther; 2021 Sep; 34(5):e15085. PubMed ID: 34350668
    [No Abstract]   [Full Text] [Related]  

  • 16. Oxford-AstraZeneca ChAdOx1 COVID-19 Vaccine Does Not Alter Platelet Aggregation.
    Limami Y; Khalki L; Zaid N; Khyatti M; Turk JE; Ammara M; Mtairag EM; Oudghiri M; Naya A; Taberkant M; Zaid Y
    Semin Thromb Hemost; 2022 Feb; 48(1):109-111. PubMed ID: 33971677
    [No Abstract]   [Full Text] [Related]  

  • 17. Relapse of minimal change disease after inactivated SARS-CoV-2 vaccination: case report.
    Özkan G; Bayrakçı N; Karabağ S; Güzel EÇ; Ulusoy S
    Int Urol Nephrol; 2022 Apr; 54(4):971-972. PubMed ID: 34181144
    [No Abstract]   [Full Text] [Related]  

  • 18. Delayed cutaneous reaction to ChAdOx1 nCoV-19 vaccine: Is it an 'AstraZeneca arm'?
    Kim JE; Lee H; Paik SS; Moon JY; Yoon HJ; Kim SH
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e711-e714. PubMed ID: 34166540
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine".
    Schwotzer N; Kissling S; Fakhouri F
    Kidney Int; 2021 Aug; 100(2):458-459. PubMed ID: 34052236
    [No Abstract]   [Full Text] [Related]  

  • 20. Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine.
    Kumar R; Kodan P; Aggarwal R; Deepak GP; Trikha A
    QJM; 2022 Jun; 115(6):423. PubMed ID: 34297134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.